TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02221037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2862277
Description: It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device.
Study: NCT03141879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HUR equipment resistance training intervention
Description: Resistance training intervention
Study: NCT02017730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]BMT-136088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]BMT-136088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]BMT-136088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]BMT-136088
Study: NCT04934150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: navigated repetitive Transcranial Stimulation
Description: High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: navigated repetitive Transcranial Stimulation
Description: High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: navigated repetitive Transcranial Stimulation
Description: High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
Study: NCT03772431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female Voice
Description: The survey was narrated by a female voice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female Voice
Description: The survey was narrated by a female voice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Introduction
Description: The survey introduction was worded to include motivational content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Introduction
Description: The survey introduction was worded to include motivational content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Male Voice
Description: The survey was narrated by a male voice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Male Voice
Description: The survey was narrated by a male voice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Introduction
Description: The survey introduction was worded to include informational content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Introduction
Description: The survey introduction was worded to include informational content
Study: NCT03359824

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Study: NCT00004135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01299805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules.
Study: NCT01363804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
Study: NCT04564261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Healthy Relationship and Safety Planning Tool
Description: The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources.
Study: NCT03977831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Cystectomy
Description: Participants are randomly and blinded assigned

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Cystectomy
Description: Participants are randomly and blinded assigned
Study: NCT00695435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBRADEX Ophthalmic Suspension
Description: TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
Description: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBREX Ophthalmic Solution
Description: TOBREX Ophthalmic Solution 1 drop each eye at baseline
Study: NCT02170948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
Study: NCT04297371

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
Study: NCT00034814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Enzyme-inducing TLP 50mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-enzyme-inducing placebo TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Non-enzyme-inducing TLP 25mg TID
Study: NCT02661841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LI-Guided Therapy
Description: Preemptive treatment according to LI monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure Guidelines
Description: Treatment according to clinical signs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure Guidelines
Description: Treatment according to clinical signs
Study: NCT00817206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro
Description: LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
Study: NCT01700985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551
Description: Applied twice daily for two weeks
Study: NCT03319576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding at 4 hours
Description: Patients will be fed 4 hours after their gastrostomy tube placement procedure.
Study: NCT00057564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (Thalidomide + Dexamethasone)
Description: Thalidomide 50mg/day + Dexamethasone 40mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B (Placebo + Dexamethasone)
Description: Placebo + Dexamethasone 40mg
Study: NCT03859076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-BP
Description: MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions \& a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, \& specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, \& stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
Study: NCT04564261

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Teen Relationship and Health Website
Description: The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
Study: NCT03746652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab, Ixazomib, Dexamethasone
Description: Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
Study: NCT03699605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VESMP
Description: . The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: , All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
Study: NCT03639519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 500Mg Chew Tab
Description: Ascorbic acid will be administered at the night before surgery and will be continued for five days
Study: NCT04297371

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
Study: NCT04620902

Intervention type: OTHER
Intervention: Tear sampling
Description: Tear sampling using Schirmer's strips
Study: NCT03859076

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
Study: NCT04792385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E4/DRSP 15/3 mg combined tablet
Description: One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
Study: NCT00998010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib + temozolomide+ radiation therapy
Description: Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
Study: NCT03830580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive stimulation (singing)
Description: A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
Study: NCT02901886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Description: The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
Study: NCT03759990

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lean
Description: Videolaryngoscope used in intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lean
Description: Videolaryngoscope used in intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: obese
Description: Videolaryngoscope used in intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: obese
Description: Videolaryngoscope used in intubation
Study: NCT01865487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56ug/IC31nmol
Description: H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56ug/IC31nmol
Description: H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56ug/IC31nmol
Description: H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56ug/IC31nmol
Description: H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
Study: NCT01441388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus VEGF inhibitor combinations
Description: Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
Study: NCT03355820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for antibody determination
Description: In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.
Study: NCT01409330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diet intervention
Description: 8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
Study: NCT01700985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Applied twice daily for two weeks
Study: NCT03140423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1. Routine Care (Mupirocin/CHG)
Description: The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
Study: NCT03788590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jenscare TAVI
Description: Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
Study: NCT01675895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine lidocaine spinal anesthesia
Description: Spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine Spinal anesthesia
Description: spinal anesthesia
Study: NCT03140423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2. Iodophor/CHG Decolonization
Description: The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
Study: NCT02534194

Intervention type: OTHER
Intervention: Image acquisition
Description: Images of baby's face (including ear) and feet
Study: NCT00895193

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple pectin
Description: Apple pectin 2000mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple pectin
Description: Apple pectin 2000mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325 mg
Description: Aspirin 325 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325 mg
Description: Aspirin 325 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03095053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive chromosome screening
Description: Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).
Study: NCT05283863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation
Description: Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-frequency stimulation
Description: Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
Study: NCT03169244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo will be initiated on Day 1 and continue throughout the course of the study.
Study: NCT02663778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: weight lifting to increase muscle strength

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: weight lifting to increase muscle strength

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: treadmill walking to increase endurance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: treadmill walking to increase endurance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training
Description: stretches to improve flexibility

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility training
Description: stretches to improve flexibility

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Specific timing and coordination training
Description: stepping and walking patterns to improve timing and coordination of gait

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity behavioral intervention
Description: Intervention to encourage participants to be more physically active

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavioral intervention
Description: Intervention to encourage participants to be more physically active